Evidence map›Paper›PMID 40330448›Full record

ArticleContemporary oncology (Poznan, Poland)2025

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Oktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, Kamil Wiśniewski, Joanna Drozd-Sokołowska, Marta Morawska, Urszula Gosik, Dariusz Woszczyk, Agata Ogłoza, Kamil Wdowiak and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Advancing Immunotherapy in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Oktawia SośniaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
Elżbieta Iskierka-JażdżewskaDepartment of General Hematology, Copernicus Memorial Hospital in Łódź, Medical University, Łódź, Poland.
Anna PułaDepartment of General Hematology, Copernicus Memorial Hospital in Łódź, Medical University, Łódź, Poland.
Kamil WiśniewskiDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
Joanna Drozd-SokołowskaDepartment of Hematology, Transplantation and Internal Medicine, Medical University, Warszawa, Poland.
Marta MorawskaHematology Department, St John's Cancer Centre, Lublin, Poland.
Urszula GosikHematology Department, St John's Cancer Centre, Lublin, Poland.
Dariusz WoszczykDepartment of Hematology, Institute of Medical Sciences, University of Opole, Opole, Poland.
Agata OgłozaDepartment of Hematology and Transplantology, Medical University, Gdańsk, Poland.
Kamil WdowiakDepartment of Internal Diseases and Oncological Chemotherapy, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland.
Ewa Paszkiewicz-KozikDepartment of Lymphoid Malignancies, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
Ewa Wąsik-SzczepanekDepartment of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland.
Mirosław MarkiewiczHematology Department, Institute of Medical Sciences, College of Medical Sciences, University, Rzeszów, Poland.
Magdalena ZawartkoDepartment of Hematology, Provincial Hospital, Szczecin, Poland.
Anna KokoćDepartment of Hematooncology and Bone Marrow Transplantation, Medical University, Lublin, Poland.
Anna Szumera-CiećkiewiczDepartment of Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Warszawa, Poland.
Monika Prochorec-SobieszekDiagnostic Hematology Department, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
Dorota Jesionek-KupnickaDepartment of Pathology, Chair of Oncology, Medical University, Łódź, Poland.
Marcin BraunDepartment of Pathology, Chair of Oncology, Medical University, Łódź, Poland.
Beata GierejDepartment of Pathomorphology, University Clinical Centre, Medical University, Warszawa, Poland.
Tadeusz RobakDepartment of General Hematology, Copernicus Memorial Hospital in Łódź, Medical University, Łódź, Poland.
Ewa Lech-MarańdaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.
Bartosz PułaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warszawa, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Accelerated chronic lymphocytic leukemia (A-CLL) is a rare histological variant of CLL, which is associated with an aggressive clinical presentation and worse prognosis. The aim was to study the characteristics and treatment outcomes of A-CLL patients. Material and methods: The retrospective analysis included 106 A-CLL patients treated in Poland between 2013 and 2023. Results: Median overall survival (OS) for treatment-naive A-CLL was 6.05 years (95% CI: 4.7-NA) and median progression-free survival (PFS) was 5.66 years (95% CI: 4.05-6.34). Factors associated with worse PFS were: Eastern Cooperative Oncology Group > 2 ( Conclusions: This study represents one of the largest datasets of A-CLL patients and shows its poorer prognosis compared to typical CLL. Chronic lymphocytic leukemia directed therapy should be considered as a treatment modality of choice for A-CLL. R-CHOP protocols are less effective.

Indexed as

accelerationchronic lymphocytic leukemiaRichter transformation

Identifiers

PMID40330448
PMCPMC12051875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.